Showing results (101-110 of 2,406) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|May 10, 2018
First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USAMichael S Broder, Beilei Cai, Eunice Chang, et al.Journal of Medical Economics|July 6, 2018
US budget impact of increased payer adoption of the Flexitouch advanced pneumatic compression device in lymphedema patients with advanced chronic venous insufficiency and multiple infectionsAdam Cohen, Julia A Gaebler, Jessica Izhakoff, et al.Journal of Medical Economics|April 21, 2018
Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United StatesLisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, et al.Journal of Medical Economics|October 23, 2021
Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States populationRuchit Shah, Shelby Corman, Anuj Shah, et al.Journal of Medical Economics|October 14, 2021
Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancerLuciano Paladini, Cássia Rita Pereira da Veiga, Érica Cerqueira, et al.Journal of Medical Economics|October 11, 2021
Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The NetherlandsLisa Aniek de Jong, Alexander Victor van Schoonhoven, Hinko Stephan Hofstra, et al.Journal of Medical Economics|October 13, 2021
Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspectiveLaurence Pollissard, Brian I Leinwand, Marie Fournier, et al.Journal of Medical Economics|October 17, 2019
Impact of multiple sclerosis phenotypes on burden of disease in FinlandTimo Purmonen, Tanja Hakkarainen, Melina Tervomaa, et al.Journal of Medical Economics|April 27, 2022
Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in ChinaMingjun Rui, Zhengyang Fei, Yingcheng Wang, et al.Journal of Medical Economics|June 15, 2019
Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasisAmanda Teeple, Erik MuserPageof 241